Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

[1]  F. Marincola,et al.  Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) , 1996, The Journal of experimental medicine.

[2]  D. Mason,et al.  A very high level of crossreactivity is an essential feature of the T-cell receptor. , 1998, Immunology today.

[3]  D. Kranz,et al.  Cd8− T Cell Transfectants That Express a High Affinity T Cell Receptor Exhibit Enhanced Peptide-Dependent Activation , 2001, The Journal of experimental medicine.

[4]  D. Baker,et al.  A simple physical model for binding energy hot spots in protein–protein complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Welsh,et al.  T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens , 2002, Nature Immunology.

[6]  David M. Kranz,et al.  TCRs with high affinity for foreign pMHC show self-reactivity , 2003, Nature Immunology.

[7]  P. Harbury,et al.  Automated design of specificity in molecular recognition , 2003, Nature Structural Biology.

[8]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[9]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[10]  Brian M Baker,et al.  Two different T cell receptors use different thermodynamic strategies to recognize the same peptide/MHC ligand. , 2005, Journal of molecular biology.

[11]  P. Katsamba,et al.  Analyzing a kinetic titration series using affinity biosensors. , 2006, Analytical biochemistry.

[12]  Robyn L Stanfield,et al.  How TCRs bind MHCs, peptides, and coreceptors. , 2006, Annual review of immunology.

[13]  H. Schmidt,et al.  Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[15]  S. Rosenberg,et al.  Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 , 2006, The Journal of Immunology.

[16]  M. Nishimura,et al.  Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells. , 2006, Cancer research.

[17]  M. Nishimura,et al.  Identification of a hepatitis C virus–reactive T cell receptor that does not require CD8 for target cell recognition , 2006, Hepatology.

[18]  A. Perelson,et al.  Polyspecificity of T cell and B cell receptor recognition. , 2007, Seminars in immunology.

[19]  Yi Li,et al.  High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines1 , 2007, The Journal of Immunology.

[20]  Philippa Marrack,et al.  Evolutionarily conserved amino acids that control TCR-MHC interaction. , 2008, Annual review of immunology.

[21]  David Baker,et al.  Macromolecular modeling with rosetta. , 2008, Annual review of biochemistry.

[22]  R. Phillips,et al.  Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor , 2008, Nature Medicine.

[23]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[24]  Gevorg Grigoryan,et al.  Design of protein-interaction specificity affords selective bZIP-binding peptides , 2009, Nature.

[25]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[26]  K. M. Armstrong,et al.  Methods for quantifying T cell receptor binding affinities and thermodynamics. , 2009, Methods in enzymology.

[27]  B. Baker,et al.  Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. , 2009, Molecular immunology.

[28]  B. Kuhlman,et al.  Computational design of affinity and specificity at protein-protein interfaces. , 2009, Current opinion in structural biology.

[29]  A. Sewell,et al.  CD8 Controls T Cell Cross-Reactivity , 2010, The Journal of Immunology.

[30]  Bruce R Donald,et al.  Predicting resistance mutations using protein design algorithms , 2010, Proceedings of the National Academy of Sciences.

[31]  J. Allison,et al.  Attenuated T Cell Responses to a High-Potency Ligand In Vivo , 2010, PLoS biology.

[32]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[33]  J. Slansky,et al.  The Goldilocks Model for TCR—Too Much Attraction Might Not Be Best for Vaccine Design , 2010, PLoS biology.

[34]  Sergey Lyskov,et al.  PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta , 2010, Bioinform..

[35]  Samuel L. DeLuca,et al.  Practically Useful: What the Rosetta Protein Modeling Suite Can Do for You , 2010, Biochemistry.

[36]  Nathaniel Echols,et al.  The Phenix software for automated determination of macromolecular structures. , 2011, Methods.

[37]  Gideon Schreiber,et al.  Protein binding specificity versus promiscuity. , 2010, Current opinion in structural biology.

[38]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Price,et al.  A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides* , 2011, The Journal of Biological Chemistry.

[40]  B. Baker,et al.  TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms , 2011, The Journal of Immunology.

[41]  Andrew K. Sewell,et al.  Why must T cells be cross-reactive? , 2012, Nature Reviews Immunology.

[42]  Katherine K. Matthews,et al.  T-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen Targeting* , 2012, The Journal of Biological Chemistry.

[43]  Zhiping Weng,et al.  Cutting Edge: Evidence for a Dynamically Driven T Cell Signaling Mechanism , 2012, The Journal of Immunology.

[44]  D. Kranz,et al.  Long-term Persistence of CD4+ but Rapid Disappearance of CD8+ T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  Olivier Michielin,et al.  Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+ T Cell Responsiveness* , 2012, The Journal of Biological Chemistry.

[46]  D. Kranz,et al.  Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[48]  Thomas M. Schmitt,et al.  Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. , 2013, Blood.

[49]  S. Rosenberg,et al.  T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy , 2013, Proceedings of the National Academy of Sciences.

[50]  D. Speiser,et al.  Molecular Insights for Optimizing T Cell Receptor Specificity Against Cancer , 2013, Front. Immunol..

[51]  David M. Kranz,et al.  Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies , 2013, Front. Immunol..

[52]  D. Speiser,et al.  SHP-1 phosphatase activity counteracts increased T cell receptor affinity. , 2013, The Journal of clinical investigation.

[53]  Mark M. Davis,et al.  Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.

[54]  Timothy Cardozo,et al.  Specific Increase in Potency via Structure-Based Design of a TCR , 2014, The Journal of Immunology.

[55]  Zhiping Weng,et al.  Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor , 2014, PLoS Comput. Biol..

[56]  James McCluskey,et al.  T cell antigen receptor recognition of antigen-presenting molecules. , 2015, Annual review of immunology.

[57]  Alimuddin Zumla,et al.  T-Cell Therapy: Options for Infectious Diseases , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  J. E. Brewer,et al.  T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells , 2015, Clinical and experimental immunology.

[59]  J. Riley,et al.  Engineering T Cells to Functionally Cure HIV-1 Infection. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  N. Singh,et al.  Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex* , 2016, The Journal of Biological Chemistry.

[61]  David M. Kranz,et al.  Structural interplay between germline and adaptive recognition determines TCR-peptide-MHC cross-reactivity , 2015, Nature Immunology.

[62]  N. Singh,et al.  An Engineered Switch in T Cell Receptor Specificity Leads to an Unusual but Functional Binding Geometry. , 2016, Structure.

[63]  Y. Wang,et al.  Hepatitis C virus‐cross‐reactive TCR gene‐modified T cells: a model for immunotherapy against diseases with genomic instability , 2016, Journal of leukocyte biology.

[64]  Y. Wang,et al.  Differential scanning fluorimetry based assessments of the thermal and kinetic stability of peptide-MHC complexes. , 2016, Journal of immunological methods.

[65]  Zhiping Weng,et al.  A generalized framework for computational design and mutational scanning of T-cell receptor binding interfaces. , 2016, Protein engineering, design & selection : PEDS.

[66]  A. Sewell,et al.  Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity , 2016, The Journal of clinical investigation.

[67]  J. Lasola,et al.  A Synthetic CD8α:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens. , 2017, Cancer research.

[68]  Kendra C. Foley,et al.  HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer , 2017, Molecular therapy oncolytics.

[69]  B. Baker,et al.  Using Global Analysis to Extend the Accuracy and Precision of Binding Measurements with T cell Receptors and Their Peptide/MHC Ligands , 2017, Front. Mol. Biosci..

[70]  C. June,et al.  Driving gene-engineered T cell immunotherapy of cancer , 2016, Cell Research.

[71]  L. Hellman,et al.  Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells , 2017, Cancer Immunology, Immunotherapy.

[72]  Z. Weng,et al.  Emerging Concepts in TCR Specificity: Rationalizing and (Maybe) Predicting Outcomes , 2017, The Journal of Immunology.

[73]  Lydia E. Kavraki,et al.  Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy , 2017, Front. Immunol..

[74]  K. Garcia,et al.  T cell receptor cross-reactivity expanded by dramatic peptide/MHC adaptability , 2018, Nature Chemical Biology.

[75]  Purvesh Khatri,et al.  Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes , 2017, Cell.

[76]  K. Christopher Garcia,et al.  Stress-testing the relationship between T cell receptor/peptide-MHC affinity and cross-reactivity using peptide velcro , 2018, Proceedings of the National Academy of Sciences.

[77]  T. P. Riley,et al.  The intersection of affinity and specificity in the development and optimization of T cell receptor based therapeutics. , 2018, Seminars in cell & developmental biology.